Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck

Andrew J. Rosko, Andrew C. Birkeland, Kevin F. Wilson, Daniel G. Muenz, Emily Bellile, Carol R. Bradford, Jonathan B. McHugh, Matthew E. Spector

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective To determine biomarkers of recurrence and survival in patients with spindle cell variant squamous cell carcinoma (SpSCC) of the head and neck. Study Design Retrospective case control study. Setting Tertiary academic center. Subjects and Methods Thirty-two SpSCC patients (mean age, 68.8) between 1987 and 2009 were identified and reviewed. A tissue microarray (TMA) was constructed from tumor specimens. Tumor biomarkers under study included p16, epidermal growth factor receptor (EGFR), p53, EZH2, cyclin D1, CD104, HGFa, p21, and cMET. An additional TMA was constructed from patients with non-SpSCC oral cavity squamous cell carcinoma for comparative purposes. The main outcomes were overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS). Results In the SpSCC cohort, tumors positive for cMet had worse OS (P <.001). Patients positive for cMet (P =.007), cyclin D1 (P =.019), and p16 (P =.004) had worse DSS. Recurrence-free survival was also worse in patients with tumors positive for cMet (P =.037), cyclin D1 (P =.012), and p16 (P <.001). Compared with the oral cavity cohort, there was a significantly larger proportion of patients in the SpSCC group with tumors staining positive for cMet and a lower proportion of tumors positive for cyclin D1. Conclusion cMet, cyclin D1, and p16 are predictive tumor biomarkers for risk of recurrence and worse DSS in patients with SpSCC.

Original languageEnglish (US)
Pages (from-to)106-112
Number of pages7
JournalOtolaryngology - Head and Neck Surgery (United States)
Volume155
Issue number1
DOIs
StatePublished - Jul 1 2016
Externally publishedYes

Fingerprint

Tumor Biomarkers
Cyclin D1
Squamous Cell Carcinoma
Survival
Recurrence
Neoplasms
Mouth
Carcinoma, squamous cell of head and neck
Epidermal Growth Factor Receptor
Case-Control Studies
Retrospective Studies
Biomarkers
Staining and Labeling

Keywords

  • biomarkers
  • cMet
  • cyclin D1
  • EGFR
  • head and neck cancer
  • p16
  • sarcomatoid
  • spindle cell

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology

Cite this

Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck. / Rosko, Andrew J.; Birkeland, Andrew C.; Wilson, Kevin F.; Muenz, Daniel G.; Bellile, Emily; Bradford, Carol R.; McHugh, Jonathan B.; Spector, Matthew E.

In: Otolaryngology - Head and Neck Surgery (United States), Vol. 155, No. 1, 01.07.2016, p. 106-112.

Research output: Contribution to journalArticle

Rosko, Andrew J. ; Birkeland, Andrew C. ; Wilson, Kevin F. ; Muenz, Daniel G. ; Bellile, Emily ; Bradford, Carol R. ; McHugh, Jonathan B. ; Spector, Matthew E. / Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck. In: Otolaryngology - Head and Neck Surgery (United States). 2016 ; Vol. 155, No. 1. pp. 106-112.
@article{1ae416a88bde44479282047e0531d4f3,
title = "Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck",
abstract = "Objective To determine biomarkers of recurrence and survival in patients with spindle cell variant squamous cell carcinoma (SpSCC) of the head and neck. Study Design Retrospective case control study. Setting Tertiary academic center. Subjects and Methods Thirty-two SpSCC patients (mean age, 68.8) between 1987 and 2009 were identified and reviewed. A tissue microarray (TMA) was constructed from tumor specimens. Tumor biomarkers under study included p16, epidermal growth factor receptor (EGFR), p53, EZH2, cyclin D1, CD104, HGFa, p21, and cMET. An additional TMA was constructed from patients with non-SpSCC oral cavity squamous cell carcinoma for comparative purposes. The main outcomes were overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS). Results In the SpSCC cohort, tumors positive for cMet had worse OS (P <.001). Patients positive for cMet (P =.007), cyclin D1 (P =.019), and p16 (P =.004) had worse DSS. Recurrence-free survival was also worse in patients with tumors positive for cMet (P =.037), cyclin D1 (P =.012), and p16 (P <.001). Compared with the oral cavity cohort, there was a significantly larger proportion of patients in the SpSCC group with tumors staining positive for cMet and a lower proportion of tumors positive for cyclin D1. Conclusion cMet, cyclin D1, and p16 are predictive tumor biomarkers for risk of recurrence and worse DSS in patients with SpSCC.",
keywords = "biomarkers, cMet, cyclin D1, EGFR, head and neck cancer, p16, sarcomatoid, spindle cell",
author = "Rosko, {Andrew J.} and Birkeland, {Andrew C.} and Wilson, {Kevin F.} and Muenz, {Daniel G.} and Emily Bellile and Bradford, {Carol R.} and McHugh, {Jonathan B.} and Spector, {Matthew E.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1177/0194599816636612",
language = "English (US)",
volume = "155",
pages = "106--112",
journal = "Otolaryngology - Head and Neck Surgery (United States)",
issn = "0194-5998",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck

AU - Rosko, Andrew J.

AU - Birkeland, Andrew C.

AU - Wilson, Kevin F.

AU - Muenz, Daniel G.

AU - Bellile, Emily

AU - Bradford, Carol R.

AU - McHugh, Jonathan B.

AU - Spector, Matthew E.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Objective To determine biomarkers of recurrence and survival in patients with spindle cell variant squamous cell carcinoma (SpSCC) of the head and neck. Study Design Retrospective case control study. Setting Tertiary academic center. Subjects and Methods Thirty-two SpSCC patients (mean age, 68.8) between 1987 and 2009 were identified and reviewed. A tissue microarray (TMA) was constructed from tumor specimens. Tumor biomarkers under study included p16, epidermal growth factor receptor (EGFR), p53, EZH2, cyclin D1, CD104, HGFa, p21, and cMET. An additional TMA was constructed from patients with non-SpSCC oral cavity squamous cell carcinoma for comparative purposes. The main outcomes were overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS). Results In the SpSCC cohort, tumors positive for cMet had worse OS (P <.001). Patients positive for cMet (P =.007), cyclin D1 (P =.019), and p16 (P =.004) had worse DSS. Recurrence-free survival was also worse in patients with tumors positive for cMet (P =.037), cyclin D1 (P =.012), and p16 (P <.001). Compared with the oral cavity cohort, there was a significantly larger proportion of patients in the SpSCC group with tumors staining positive for cMet and a lower proportion of tumors positive for cyclin D1. Conclusion cMet, cyclin D1, and p16 are predictive tumor biomarkers for risk of recurrence and worse DSS in patients with SpSCC.

AB - Objective To determine biomarkers of recurrence and survival in patients with spindle cell variant squamous cell carcinoma (SpSCC) of the head and neck. Study Design Retrospective case control study. Setting Tertiary academic center. Subjects and Methods Thirty-two SpSCC patients (mean age, 68.8) between 1987 and 2009 were identified and reviewed. A tissue microarray (TMA) was constructed from tumor specimens. Tumor biomarkers under study included p16, epidermal growth factor receptor (EGFR), p53, EZH2, cyclin D1, CD104, HGFa, p21, and cMET. An additional TMA was constructed from patients with non-SpSCC oral cavity squamous cell carcinoma for comparative purposes. The main outcomes were overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS). Results In the SpSCC cohort, tumors positive for cMet had worse OS (P <.001). Patients positive for cMet (P =.007), cyclin D1 (P =.019), and p16 (P =.004) had worse DSS. Recurrence-free survival was also worse in patients with tumors positive for cMet (P =.037), cyclin D1 (P =.012), and p16 (P <.001). Compared with the oral cavity cohort, there was a significantly larger proportion of patients in the SpSCC group with tumors staining positive for cMet and a lower proportion of tumors positive for cyclin D1. Conclusion cMet, cyclin D1, and p16 are predictive tumor biomarkers for risk of recurrence and worse DSS in patients with SpSCC.

KW - biomarkers

KW - cMet

KW - cyclin D1

KW - EGFR

KW - head and neck cancer

KW - p16

KW - sarcomatoid

KW - spindle cell

UR - http://www.scopus.com/inward/record.url?scp=84976876902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976876902&partnerID=8YFLogxK

U2 - 10.1177/0194599816636612

DO - 10.1177/0194599816636612

M3 - Article

C2 - 26980915

AN - SCOPUS:84976876902

VL - 155

SP - 106

EP - 112

JO - Otolaryngology - Head and Neck Surgery (United States)

JF - Otolaryngology - Head and Neck Surgery (United States)

SN - 0194-5998

IS - 1

ER -